Clinical Trial

Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase 2 single-arm, open-label clinical trial determining efficacy of cabozantinib in combination with ipilimumab/nivolumab and transarterial chemoembolization (TACE) in subjects with hepatocellular carcinoma (HCC). These are subjects who are not candidates for curative intent treatment.
Protocol Amendment History 1 change
notable Primary completion pushed: 2026-06-01 -> 2026-10-01 2026-07-02
Trial Details
NCT Number NCT04472767
Lead Sponsor University of California, Irvine
Collaborators: Exelixis
Conditions Hepatocellular Carcinoma, HCC
Enrollment 35 participants
Start Date 2020-08-07
Primary Completion 2026-10-01 (estimated)
Study Completion 2027-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-01